News|Articles|July 6, 2026

6 Hepatology Headlines You Missed in June 2026

Catch up on the latest in hepatology, from bulevirtide’s FDA approval for hepatitis delta to expert perspectives on new and emerging therapies in PBC, PSC, and MASLD.

June was another eventful month in hepatology, with new insights into viral hepatitis, cholestatic liver diseases, and metabolic dysfunction-associated steatotic liver disease (MASLD) continuing to reshape clinical practice. From expert discussions on newly approved therapies to emerging data on disease progression and cardiometabolic risk, the month's developments highlighted the increasingly personalized approach to liver disease management.